SwePub
Sök i LIBRIS databas

  Utökad sökning

L773:1432 0851
 

Sökning: L773:1432 0851 > Histamine targets m...

Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade

Grauers Wiktorin, Hanna, 1990 (författare)
Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center
Nilsson, Malin S. (författare)
Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center
Kiffin, Roberta (författare)
Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center
visa fler...
Sander, Frida Ewald (författare)
Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center
Lenox, Brianna (författare)
Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center
Rydström, Anna, 1976 (författare)
Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center
Hellstrand, Kristoffer, 1956 (författare)
Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center
Martner, Anna, 1979 (författare)
Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center
visa färre...
 (creator_code:org_t)
2018-10-12
2019
Engelska.
Ingår i: Cancer Immunology Immunotherapy. - : Springer Science and Business Media LLC. - 0340-7004 .- 1432-0851. ; 68:2, s. 163-174
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Myeloid-derived suppressor cells (MDSCs) are immature monocytes and granulocytes that impede immune-mediated clearance of malignant cells by multiple mechanisms, including the formation of immunosuppressive reactive oxygen species (ROS) via the myeloid cell NADPH oxidase (NOX2). Histamine dihydrochloride (HDC), a NOX2 inhibitor, exerts anti-cancer efficacy in experimental tumor models but the detailed mechanisms are insufficiently understood. To determine effects of HDC on the MDSC compartment we utilized three murine cancer models known to entail accumulation of MDSC, i.e. EL-4 lymphoma, MC-38 colorectal carcinoma, and 4T1 mammary carcinoma. In vivo treatment with HDC delayed EL-4 and 4T1 tumor growth and reduced the ROS formation by intratumoral MDSCs. HDC treatment of EL-4 bearing mice also reduced the accumulation of intratumoral MDSCs and reduced MDSC-induced suppression of T cells ex vivo. Experiments using GR1-depleted and Nox2 knock out mice supported that the anti-tumor efficacy of HDC required presence of NOX2(+) GR1(+) cells in vivo. In addition, treatment with HDC enhanced the anti-tumor efficacy of programmed cell death receptor 1 (PD-1) and PD-1 ligand checkpoint blockade in EL-4- and MC-38-bearing mice. Immunomodulatory effects of a HDC-containing regimen on MDSCs were further analyzed in a phase IV trial (Re:Mission Trial, ClinicalTrials.gov; NCT01347996) where patients with acute myeloid leukemia received HDC in conjunction with low-dose IL-2 (HDC/IL-2) for relapse prevention. Peripheral CD14(+)HLA-DR-/low MDSCs (M-MDSCs) were reduced during cycles of HDC/IL-2 therapy and a pronounced reduction of M-MDSCs during HDC/IL-2 treatment heralded favorable clinical outcome. We propose that anti-tumor properties of HDC may comprise the targeting of MDSCs.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

Myeloid-derived suppressor cells
Histamine dihydrochloride
NOX2
Reactive oxygen species
PD-1
Checkpoint inhibition
immune-response
mechanism
infiltration
melanoma
promotes
mdscs
Oncology
Immunology

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy